English | 简体中文 | 繁體中文 | 한국어 | 日本語
  Press Releases
Tuesday, July 19, 2016
エーザイ、米国FDAが肥満症治療剤lorcaserinの1日1回製剤「BELVIQ XR(R)」を承認
Thursday, July 14, 2016
エーザイ、抗肥満症治療剤「VENESPRI(R)」がメキシコで承認取得
Monday, July 11, 2016
NTTアイティ・NTT東日本・エーザイ、医療・介護における多職種連携事業を展開
Monday, July 4, 2016
エーザイ、自社創製の新規抗がん剤「レンビマ(R)」をメキシコで発売
Thursday, June 30, 2016
エーザイ、社会的責任投資指数「FTSE4Good Index Series」の対象銘柄に15年連続で選定
Eisai listed for 15th Consecutive Year FTSE4Good Index Series, an Index for Socially Responsible Investment
Monday, June 20, 2016
アッヴィとエーザイなど、「ヒュミラ」のクローン病に対する用法・用量の追加承認を取得
AbbVie, Eisai, and EA Pharma Obtain Additional Approval for New Dosing Regimen of Fully Human Anti-TNF Monoclonal Antibody Humira in Patients with Crohn's Disease
Thursday, June 16, 2016
Eisai Launches New Oral Suspension Formulation for Antiepileptic Drug Fycompa (Perampanel) in the United States
エーザイ、米国において抗てんかん剤「Fycompa」経口懸濁液を発売

Copyright © 2024 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Cookies Policy | Privacy Policy | Disclaimer | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575